FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 383 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer April 4, 2019 Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That... March 19, 2020 Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... July 3, 2023 Load more HOT NEWS Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer... An apple a day keeps the doctor away FDA Approves New and Updated Indications for Temozolomide Under Project Renewal
